Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis …
W Zhang, Z Liang, Y Zhao, Y Li, T Chen, W Li… - Frontiers in …, 2024 - frontiersin.org
Objective At present, several important trials have been published show that perioperative
immunotherapy combined with chemotherapy can improve the prognosis of patients with …
immunotherapy combined with chemotherapy can improve the prognosis of patients with …
“Percentage” and “size” of residual viable tumor in lymph node, the performance in estimating pathologic response of lymph node in non-small cell lung cancer treated …
W Sun, L Qu, J Wu, X Liu, C Wang, Y Jiang, Y Liu… - Human Pathology, 2024 - Elsevier
There is no universally accepted method for evaluating lymph node metastasis (LNM) in non-
small cell lung cancer (NSCLC) after neoadjuvant chemoimmunotherapy. Different protocols …
small cell lung cancer (NSCLC) after neoadjuvant chemoimmunotherapy. Different protocols …
Impact of recurrence on employment, finances, and productivity for early-stage cancer patients and caregivers: US survey
R Aguiar-Ibáñez, K McQuarrie, S Jayade… - Future …, 2024 - Taylor & Francis
Background Following an early-stage cancer diagnosis, recurrences can occur. To quantify
financial impacts of a first recurrence, we surveyed patients and caregivers. Methods The …
financial impacts of a first recurrence, we surveyed patients and caregivers. Methods The …
Comparison of different criteria for estimating major pathological response in resectable non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy
W Sun, X Liu, C Wang, Y Jiang, D Lin - Annals of Diagnostic Pathology, 2024 - Elsevier
Background Major pathological response (MPR) is proposed as a surrogate endpoint for
survival in non-small cell lung cancer (NSCLC) after neoadjuvant chemoimmunotherapy …
survival in non-small cell lung cancer (NSCLC) after neoadjuvant chemoimmunotherapy …